世界の微小生理学的システム市場は、2025年に250百万米ドルと算定されており、2026年には292百万米ドルとなる見通しです。2026年から2032年の期間においては年平均成長率（CAGR）16.2%で推移し、2032年には719百万米ドルに達すると予測されています。

微小生理学的システムの市場規模、推定値、予測値は売上収益で提示され、2025年を基準年とし、2021年から2032年までの過去データと予測データを含みます。本レポートは定量的・定性的分析を組み合わせ、企業が成長戦略の策定、競争環境の評価、現在の市場における自社の位置付けの分析、微小生理学的システムに関する情報に基づいたビジネス判断を行うことを支援します。
報告対象範囲
売上高予測、企業シェア、競争環境、成長要因および市場トレンド

市場セグメンテーション
企業一覧
Emulate
MIMETAS
TissUse
CN Bio Innovations
AIM Biotech
AlveoliX
Beonchip
React4life
InSphero
NETRI
SynVivo
BiomimX
Dynamic42
Kirkstall
Cherry Biotech
Micronit
Cellbox Labs
REVIVO BioSystems
MesoBioTech
Beijing Daxiang Biotech
AVATARGET
Suzhou Jiyan Biopharmaceutical
Altis Biosystems
28bio
Bi/ond
Ananda Devices


タイプ別
Liver MPS
Lung MPS
Cardiac MPS
Kidney MPS
Gastrointestinal MPS
Neural/Brain MPS
Other


用途別
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others


地域別
北米（アメリカ、カナダ、メキシコ）
欧州（ドイツ、フランス、イギリス、イタリアなど）
アジア太平洋（中国、日本、韓国、東南アジア、インドなど）
南米（ブラジルなど）
中東・アフリカ（トルコ、GCC諸国、アフリカなど）
グローバル微小生理学的システム市場を包括的にセグメント化しております。地域別市場規模、タイプ別、用途別、およびプレイヤー別の市場規模も提供されます。より深い洞察を得るため、本レポートでは競争環境、主要競合他社、それぞれの市場順位を分析し、技術動向や新製品開発について論じております。
本レポートの構成
第1章：微小生理学的システム市場の調査範囲および各市場セグメント（タイプ別、用途別など）のエグゼクティブサマリーを紹介いたします。市場規模や将来の発展可能性を含め、現状ならびに短期・中期・長期の動向について概観を提供いたします
第2章：微小生理学的システムの世界市場規模および地域別市場規模の概要を提示いたします。あわせて、市場トレンド、最新動向、成長を促進する要因と抑制要因、業界企業が直面する課題・リスク、関連政策について分析いたします
第3章：微小生理学的システム市場における企業の競争環境、収益シェア、最新の事業計画、合併・買収（M&A）情報などを詳細に分析いたします
第4章：微小生理学的システム市場をタイプ別に分類し、各セグメントの市場規模および成長余地を提示いたします
第5章：微小生理学的システム市場を用途別に整理し、各セグメントの市場規模および拡大可能性を明らかにいたします
第6章～第10章：微小生理学的システム市場について、北米、欧州、アジア太平洋、中南米、中東・アフリカを対象に国別分析を実施いたします。各地域および主要国の市場規模、発展可能性、生産能力、市場の成熟度、将来見通しを定量的に評価いたします
第11章：微小生理学的システム市場の主要プレイヤーの企業プロファイルを提供いたします。収益、粗利益率、製品ポートフォリオ、最近の事業展開などを網羅的に整理いたします
第12章：微小生理学的システム市場に関する重要な知見を総括し、結論を提示いたします
第13章：付録（調査方法論）

The global Microphysiological System market was valued at US$ 250 million in 2025 and is anticipated to reach US$ 719 million by 2032, at a CAGR of 16.2% from 2026 to 2032.

Microphysiological Systems (MPS) are advanced in vitro models that use human-derived cells, tissues, or organoids together with technologies such as three-dimensional culture, microfluidics, extracellular matrices, dynamic perfusion, mechanical stimulation, and integrated sensing to reproduce key structural, functional, and physiological characteristics of human tissues or organs. MPS include Organ-on-Chip systems, multi-organ platforms, organoid-based MPS, and certain engineered 3D tissue models. These systems can simulate cell-cell interactions, tissue barriers, fluid shear stress, and inter-organ communication. They are mainly used for drug screening, ADME/DMPK studies, toxicology assessment, disease modeling, precision medicine, and the reduction or replacement of animal testing, with the goal of improving the human relevance and predictive value of preclinical research.Microphysiological Systems (MPS) vary significantly in price depending on platform format, cell source, tissue model complexity, throughput, and the level of integration with perfusion, imaging, and automation. In 2025–2026, basic MPS chips or 3D culture consumables are generally priced at around US$50–1,000 per chip or plate, while complex human cell-based or organoid model kits typically range from US$500–5,000 per kit. Platforms equipped with pumping, perfusion, or culture-control functions generally cost about US$5,000–30,000 per system, while high-throughput automated MPS workstations may reach US$50,000–150,000 or more per system.

The upstream value chain mainly includes human primary cells, induced pluripotent stem cells, organoids, culture media, extracellular matrices, hydrogels, PDMS, COC/COP, glass, porous membranes, sensors, and microfluidic components. Midstream companies develop and integrate MPS chips, 3D tissue models, perfusion-control devices, and automated platforms. Downstream users mainly include pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, and regulatory agencies. MPS platforms are primarily used for drug screening, ADME/DMPK studies, toxicology assessment, disease modeling, precision medicine, and the reduction or replacement of animal testing.

Market Drivers
Growing Regulatory Support for Non-Animal Testing Methods
Regulatory agencies are increasingly encouraging the use of New Approach Methodologies, including microphysiological systems, organ-on-chip platforms, organoids, and computational models. In April 2025, the FDA released a roadmap to reduce reliance on animal testing in preclinical safety studies and specifically highlighted human-based models such as organ-on-chip systems. This regulatory shift is strengthening demand for validated MPS platforms in pharmaceutical safety and efficacy assessment.

Increasing Demand for Human-Relevant Preclinical Models
Traditional 2D cell cultures often fail to reproduce complex tissue architecture and physiological functions, while animal models may show species-specific differences in metabolism, immune response, and drug toxicity. MPS platforms recreate important biochemical, mechanical, and physiological conditions using human-derived cells and tissues, improving their potential to predict human drug responses and supporting broader adoption in drug discovery and development.

Rising Pharmaceutical R&D Efficiency Requirements
Pharmaceutical and biotechnology companies are seeking technologies that can identify ineffective or toxic candidates earlier in development. MPS platforms can support drug screening, ADME/DMPK studies, toxicity testing, disease modeling, and efficacy assessment using physiologically relevant human models. NIH continues to support tissue-chip programs designed to improve predictions of drug safety and toxicity in humans, strengthening the technology’s position within preclinical research workflows.

Market Restraints
High Platform and Experimental Costs
MPS experiments may require specialized chips or culture plates, human primary or stem-cell-derived cells, extracellular matrices, sensors, perfusion equipment, imaging systems, and dedicated analytical workflows. These requirements make MPS studies more expensive and operationally demanding than conventional 2D cell culture, particularly for small biotechnology companies and academic laboratories with limited budgets.

Insufficient Standardization and Reproducibility
Commercial MPS platforms differ substantially in materials, channel architecture, cell sources, extracellular matrices, flow conditions, assay endpoints, and operating protocols. This heterogeneity can create challenges in comparing results between laboratories and platforms. Wider regulatory and pharmaceutical adoption therefore requires improved quality control, reproducibility, standardized reporting, and fit-for-purpose validation criteria. OECD guidance increasingly emphasizes quality-management and fit-for-purpose considerations for MPS-related regulatory data.

Dependence on High-Quality Human Cells and Biological Materials
MPS performance is highly dependent on primary human cells, induced pluripotent stem-cell-derived cells, organoids, culture media, and extracellular matrices. Variability between donors and production batches, limited availability of certain mature cell types, and difficulties maintaining stable phenotypes during long-term culture can reduce reproducibility and complicate large-scale deployment. Market Opportunities
Expansion into Regulatory Toxicology and Safety Assessment
One of the largest opportunities for MPS is its transition from an academic research tool to a qualified platform for regulatory and industrial safety assessment. Liver, cardiac, kidney, lung, immune, and barrier models have particular potential for evaluating organ-specific toxicity. FDA and NIH collaboration on New Approach Methodologies is creating a more favorable environment for validated human-based models to enter formal drug-development workflows.

Development of High-Throughput and Automated MPS Platforms
Integration with multi-well formats, automated liquid handling, high-content imaging, biosensors, and data-analysis software can substantially increase MPS throughput and reproducibility. The industry is moving beyond manually operated individual chips toward scalable platforms capable of running dozens or hundreds of tissue models simultaneously, making MPS more compatible with pharmaceutical screening workflows and increasing recurring demand for consumables.

Integration with Organoids, iPSC Technology and AI
Combining MPS with patient-derived organoids, induced pluripotent stem cells, gene editing, and artificial intelligence can enable more disease-specific and patient-specific models. Such platforms could support precision medicine, patient stratification, rare-disease research, and prediction of individual drug responses. Multi-organ MPS further creates opportunities for studying systemic pharmacology, PK/PD relationships, metabolism, and organ-to-organ interactions.

Market Challenges
Balancing Physiological Complexity with Throughput and Scalability
Increasing biological realism often requires multiple cell types, vascular interfaces, extracellular matrices, mechanical stimulation, dynamic perfusion, and real-time sensing. However, greater complexity usually increases operating difficulty, cost, variability, and assay duration. Achieving sufficient physiological relevance while maintaining reproducibility, throughput, automation, and commercial scalability remains a fundamental technical challenge.

Extensive Validation Required for Regulatory Acceptance
Regulatory interest in MPS is increasing, but formal use in decision-making requires robust evidence demonstrating reproducibility, reliability, defined applicability domains, and correlation with human clinical outcomes. Cross-laboratory studies, reference-compound testing, standardized protocols, and comparison against existing methods remain necessary before individual MPS models can achieve broad regulatory acceptance.

Fragmentation of Technologies and Commercial Platforms
The MPS market includes organ-on-chip systems, organoid-based models, engineered 3D tissues, membrane and membrane-free platforms, passive and pump-driven systems, and single- and multi-organ configurations. No single architecture has emerged as the universal industry standard. This fragmentation increases platform-selection risks for pharmaceutical companies and creates significant R&D and commercialization challenges for MPS suppliers.

Report Scope
This report delivers a comprehensive overview of the global Microphysiological System market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Microphysiological System. The Microphysiological System market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Microphysiological System market comprehensively. Regional market sizes by Type, by End User, by System Integration, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Microphysiological System manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by End User, and by region.

Market Segmentation
By Company
Emulate
MIMETAS
TissUse
CN Bio Innovations
AIM Biotech
AlveoliX
Beonchip
React4life
InSphero
NETRI
SynVivo
BiomimX
Dynamic42
Kirkstall
Cherry Biotech
Micronit
Cellbox Labs
REVIVO BioSystems
MesoBioTech
Beijing Daxiang Biotech
AVATARGET
Suzhou Jiyan Biopharmaceutical
Altis Biosystems
28bio
Bi/ond
Ananda Devices

Segment by Type
Liver MPS
Lung MPS
Cardiac MPS
Kidney MPS
Gastrointestinal MPS
Neural/Brain MPS
Other

Segment by System Integration
Single-organ MPS
Multi-organ MPS

Segment by Platform Type
Organ-on-Chip Systems
Organoid-based MPS
3D Engineered Tissue MPS
Others

Segment by End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others

By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA

Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by End User, by System Integration, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Microphysiological System companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by End User, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Microphysiological System Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Liver MPS
1.2.3 Lung MPS
1.2.4 Cardiac MPS
1.2.5 Kidney MPS
1.2.6 Gastrointestinal MPS
1.2.7 Neural/Brain MPS
1.2.8 Other
1.3 Market by System Integration
1.3.1 Global Microphysiological System Market Size Growth Rate by System Integration: 2021 vs 2025 vs 2032
1.3.2 Single-organ MPS
1.3.3 Multi-organ MPS
1.4 Market by Platform Type
1.4.1 Global Microphysiological System Market Size Growth Rate by Platform Type: 2021 vs 2025 vs 2032
1.4.2 Organ-on-Chip Systems
1.4.3 Organoid-based MPS
1.4.4 3D Engineered Tissue MPS
1.4.5 Others
1.5 Market by End User
1.5.1 Global Microphysiological System Market Growth by End User: 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical & Biotechnology Companies
1.5.3 Academic & Research Institutes
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends
2.1 Global Microphysiological System Market Perspective (2021–2032)
2.2 Global Microphysiological System Growth Trends by Region
2.2.1 Global Microphysiological System Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Microphysiological System Historic Market Size by Region (2021–2026)
2.2.3 Microphysiological System Forecasted Market Size by Region (2027–2032)
2.3 Microphysiological System Market Dynamics
2.3.1 Microphysiological System Industry Trends
2.3.2 Microphysiological System Market Drivers
2.3.3 Microphysiological System Market Challenges
2.3.4 Microphysiological System Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Microphysiological System Players by Revenue
3.1.1 Global Top Microphysiological System Players by Revenue (2021–2026)
3.1.2 Global Microphysiological System Revenue Market Share by Players (2021–2026)
3.2 Global Top Microphysiological System Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Microphysiological System Revenue
3.4 Global Microphysiological System Market Concentration Ratio
3.4.1 Global Microphysiological System Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Microphysiological System Revenue in 2025
3.5 Global Key Players of Microphysiological System Head Offices and Areas Served
3.6 Global Key Players of Microphysiological System, Products and Applications
3.7 Global Key Players of Microphysiological System, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans

4 Microphysiological System Breakdown Data by Type
4.1 Global Microphysiological System Historic Market Size by Type (2021–2026)
4.2 Global Microphysiological System Forecasted Market Size by Type (2027–2032)

5 Microphysiological System Breakdown Data by End User
5.1 Global Microphysiological System Historic Market Size by End User (2021–2026)
5.2 Global Microphysiological System Forecasted Market Size by End User (2027–2032)

6 North America
6.1 North America Microphysiological System Market Size (2021–2032)
6.2 North America Microphysiological System Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Microphysiological System Market Size by Country (2021–2026)
6.4 North America Microphysiological System Market Size by Country (2027–2032)
6.5 United States
6.6 Canada

7 Europe
7.1 Europe Microphysiological System Market Size (2021–2032)
7.2 Europe Microphysiological System Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Microphysiological System Market Size by Country (2021–2026)
7.4 Europe Microphysiological System Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland

8 Asia-Pacific
8.1 Asia-Pacific Microphysiological System Market Size (2021–2032)
8.2 Asia-Pacific Microphysiological System Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Microphysiological System Market Size by Region (2021–2026)
8.4 Asia-Pacific Microphysiological System Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand

9 Latin America
9.1 Latin America Microphysiological System Market Size (2021–2032)
9.2 Latin America Microphysiological System Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Microphysiological System Market Size by Country (2021–2026)
9.4 Latin America Microphysiological System Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Microphysiological System Market Size (2021–2032)
10.2 Middle East & Africa Microphysiological System Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Microphysiological System Market Size by Country (2021–2026)
10.4 Middle East & Africa Microphysiological System Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE

11 Key Players Profiles
11.1 Emulate
11.1.1 Emulate Company Details
11.1.2 Emulate Business Overview
11.1.3 Emulate Microphysiological System Introduction
11.1.4 Emulate Revenue in Microphysiological System Business (2021–2026)
11.1.5 Emulate Recent Development
11.2 MIMETAS
11.2.1 MIMETAS Company Details
11.2.2 MIMETAS Business Overview
11.2.3 MIMETAS Microphysiological System Introduction
11.2.4 MIMETAS Revenue in Microphysiological System Business (2021–2026)
11.2.5 MIMETAS Recent Development
11.3 TissUse
11.3.1 TissUse Company Details
11.3.2 TissUse Business Overview
11.3.3 TissUse Microphysiological System Introduction
11.3.4 TissUse Revenue in Microphysiological System Business (2021–2026)
11.3.5 TissUse Recent Development
11.4 CN Bio Innovations
11.4.1 CN Bio Innovations Company Details
11.4.2 CN Bio Innovations Business Overview
11.4.3 CN Bio Innovations Microphysiological System Introduction
11.4.4 CN Bio Innovations Revenue in Microphysiological System Business (2021–2026)
11.4.5 CN Bio Innovations Recent Development
11.5 AIM Biotech
11.5.1 AIM Biotech Company Details
11.5.2 AIM Biotech Business Overview
11.5.3 AIM Biotech Microphysiological System Introduction
11.5.4 AIM Biotech Revenue in Microphysiological System Business (2021–2026)
11.5.5 AIM Biotech Recent Development
11.6 AlveoliX
11.6.1 AlveoliX Company Details
11.6.2 AlveoliX Business Overview
11.6.3 AlveoliX Microphysiological System Introduction
11.6.4 AlveoliX Revenue in Microphysiological System Business (2021–2026)
11.6.5 AlveoliX Recent Development
11.7 Beonchip
11.7.1 Beonchip Company Details
11.7.2 Beonchip Business Overview
11.7.3 Beonchip Microphysiological System Introduction
11.7.4 Beonchip Revenue in Microphysiological System Business (2021–2026)
11.7.5 Beonchip Recent Development
11.8 React4life
11.8.1 React4life Company Details
11.8.2 React4life Business Overview
11.8.3 React4life Microphysiological System Introduction
11.8.4 React4life Revenue in Microphysiological System Business (2021–2026)
11.8.5 React4life Recent Development
11.9 InSphero
11.9.1 InSphero Company Details
11.9.2 InSphero Business Overview
11.9.3 InSphero Microphysiological System Introduction
11.9.4 InSphero Revenue in Microphysiological System Business (2021–2026)
11.9.5 InSphero Recent Development
11.10 NETRI
11.10.1 NETRI Company Details
11.10.2 NETRI Business Overview
11.10.3 NETRI Microphysiological System Introduction
11.10.4 NETRI Revenue in Microphysiological System Business (2021–2026)
11.10.5 NETRI Recent Development
11.11 SynVivo
11.11.1 SynVivo Company Details
11.11.2 SynVivo Business Overview
11.11.3 SynVivo Microphysiological System Introduction
11.11.4 SynVivo Revenue in Microphysiological System Business (2021–2026)
11.11.5 SynVivo Recent Development
11.12 BiomimX
11.12.1 BiomimX Company Details
11.12.2 BiomimX Business Overview
11.12.3 BiomimX Microphysiological System Introduction
11.12.4 BiomimX Revenue in Microphysiological System Business (2021–2026)
11.12.5 BiomimX Recent Development
11.13 Dynamic42
11.13.1 Dynamic42 Company Details
11.13.2 Dynamic42 Business Overview
11.13.3 Dynamic42 Microphysiological System Introduction
11.13.4 Dynamic42 Revenue in Microphysiological System Business (2021–2026)
11.13.5 Dynamic42 Recent Development
11.14 Kirkstall
11.14.1 Kirkstall Company Details
11.14.2 Kirkstall Business Overview
11.14.3 Kirkstall Microphysiological System Introduction
11.14.4 Kirkstall Revenue in Microphysiological System Business (2021–2026)
11.14.5 Kirkstall Recent Development
11.15 Cherry Biotech
11.15.1 Cherry Biotech Company Details
11.15.2 Cherry Biotech Business Overview
11.15.3 Cherry Biotech Microphysiological System Introduction
11.15.4 Cherry Biotech Revenue in Microphysiological System Business (2021–2026)
11.15.5 Cherry Biotech Recent Development
11.16 Micronit
11.16.1 Micronit Company Details
11.16.2 Micronit Business Overview
11.16.3 Micronit Microphysiological System Introduction
11.16.4 Micronit Revenue in Microphysiological System Business (2021–2026)
11.16.5 Micronit Recent Development
11.17 Cellbox Labs
11.17.1 Cellbox Labs Company Details
11.17.2 Cellbox Labs Business Overview
11.17.3 Cellbox Labs Microphysiological System Introduction
11.17.4 Cellbox Labs Revenue in Microphysiological System Business (2021–2026)
11.17.5 Cellbox Labs Recent Development
11.18 REVIVO BioSystems
11.18.1 REVIVO BioSystems Company Details
11.18.2 REVIVO BioSystems Business Overview
11.18.3 REVIVO BioSystems Microphysiological System Introduction
11.18.4 REVIVO BioSystems Revenue in Microphysiological System Business (2021–2026)
11.18.5 REVIVO BioSystems Recent Development
11.19 MesoBioTech
11.19.1 MesoBioTech Company Details
11.19.2 MesoBioTech Business Overview
11.19.3 MesoBioTech Microphysiological System Introduction
11.19.4 MesoBioTech Revenue in Microphysiological System Business (2021–2026)
11.19.5 MesoBioTech Recent Development
11.20 Beijing Daxiang Biotech
11.20.1 Beijing Daxiang Biotech Company Details
11.20.2 Beijing Daxiang Biotech Business Overview
11.20.3 Beijing Daxiang Biotech Microphysiological System Introduction
11.20.4 Beijing Daxiang Biotech Revenue in Microphysiological System Business (2021–2026)
11.20.5 Beijing Daxiang Biotech Recent Development
11.21 AVATARGET
11.21.1 AVATARGET Company Details
11.21.2 AVATARGET Business Overview
11.21.3 AVATARGET Microphysiological System Introduction
11.21.4 AVATARGET Revenue in Microphysiological System Business (2021–2026)
11.21.5 AVATARGET Recent Development
11.22 Suzhou Jiyan Biopharmaceutical
11.22.1 Suzhou Jiyan Biopharmaceutical Company Details
11.22.2 Suzhou Jiyan Biopharmaceutical Business Overview
11.22.3 Suzhou Jiyan Biopharmaceutical Microphysiological System Introduction
11.22.4 Suzhou Jiyan Biopharmaceutical Revenue in Microphysiological System Business (2021–2026)
11.22.5 Suzhou Jiyan Biopharmaceutical Recent Development
11.23 Altis Biosystems
11.23.1 Altis Biosystems Company Details
11.23.2 Altis Biosystems Business Overview
11.23.3 Altis Biosystems Microphysiological System Introduction
11.23.4 Altis Biosystems Revenue in Microphysiological System Business (2021–2026)
11.23.5 Altis Biosystems Recent Development
11.24 28bio
11.24.1 28bio Company Details
11.24.2 28bio Business Overview
11.24.3 28bio Microphysiological System Introduction
11.24.4 28bio Revenue in Microphysiological System Business (2021–2026)
11.24.5 28bio Recent Development
11.25 Bi/ond
11.25.1 Bi/ond Company Details
11.25.2 Bi/ond Business Overview
11.25.3 Bi/ond Microphysiological System Introduction
11.25.4 Bi/ond Revenue in Microphysiological System Business (2021–2026)
11.25.5 Bi/ond Recent Development
11.26 Ananda Devices
11.26.1 Ananda Devices Company Details
11.26.2 Ananda Devices Business Overview
11.26.3 Ananda Devices Microphysiological System Introduction
11.26.4 Ananda Devices Revenue in Microphysiological System Business (2021–2026)
11.26.5 Ananda Devices Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer